Peripheral blood and other biological fluids were historically investigated to detect and monitor cancer and metastatic processes, especially in hematological malignancies. Traditionally, the studies focus on Circulating Tumor Cells (CTCs) and their molecular fingerprint to evaluate disease status and response to treatments, evaluating minimal residual disease (MRD). Recently the discovery of other tumor elements found in these
fluids has enhanced the interest in liquid biopsy and enabled it to enter into clinical practice. Circulating tumor DNA (ctDNA), plasma cell-free DNA (cfDNA), circulating-free RNAs (cfRNA) or extracellular vesicles (EVs, or exosomes) are emerging markers that trigger the evolution of liquid biopsy.
Liquid biopsy is a promising field of research with an enormous potential to facilitate the diagnosis, anticipate the treatment response and improve the final health care of the cancer patient, particularly for hematological malignancies. Currently, liquid biopsy has a myriad of limitations that should be addressed, such as the quantity and quality of material, the correlation of genetic signatures and patient outcomes, and the optimization of the markers collection and analysis.
This Research Topic aims to showcase studies and reviews that engage key issues in liquid biopsy in hematological malignancies, gaps in technology, protocols optimization and normalization, comparison of different markers, and correlation with traditional non-liquid biopsy monitoring.
The current Research Topic aims to cover novel research trends in the use of liquid biopsy in hematological malignancies. We welcome the submission of Case Report, Original Research, Review, Mini Review, Methods, Clinical Trial, Perspective, and Opinion articles. Investigations to be covered in this Research Topic may include, but are not limited to:
- Use of Liquid biopsy and minimal residual disease in hematological malignancies
- Integration of liquid biopsy into the clinical workflow for hematological malignancies
- Optimization and normalization of liquid biopsy protocols
- Comparison of different liquid biopsy biomarkers for use in hematological malignancies
- Correlation of liquid biopsy with non-liquid biopsy traditional minimal residual disease techniques
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
Peripheral blood and other biological fluids were historically investigated to detect and monitor cancer and metastatic processes, especially in hematological malignancies. Traditionally, the studies focus on Circulating Tumor Cells (CTCs) and their molecular fingerprint to evaluate disease status and response to treatments, evaluating minimal residual disease (MRD). Recently the discovery of other tumor elements found in these
fluids has enhanced the interest in liquid biopsy and enabled it to enter into clinical practice. Circulating tumor DNA (ctDNA), plasma cell-free DNA (cfDNA), circulating-free RNAs (cfRNA) or extracellular vesicles (EVs, or exosomes) are emerging markers that trigger the evolution of liquid biopsy.
Liquid biopsy is a promising field of research with an enormous potential to facilitate the diagnosis, anticipate the treatment response and improve the final health care of the cancer patient, particularly for hematological malignancies. Currently, liquid biopsy has a myriad of limitations that should be addressed, such as the quantity and quality of material, the correlation of genetic signatures and patient outcomes, and the optimization of the markers collection and analysis.
This Research Topic aims to showcase studies and reviews that engage key issues in liquid biopsy in hematological malignancies, gaps in technology, protocols optimization and normalization, comparison of different markers, and correlation with traditional non-liquid biopsy monitoring.
The current Research Topic aims to cover novel research trends in the use of liquid biopsy in hematological malignancies. We welcome the submission of Case Report, Original Research, Review, Mini Review, Methods, Clinical Trial, Perspective, and Opinion articles. Investigations to be covered in this Research Topic may include, but are not limited to:
- Use of Liquid biopsy and minimal residual disease in hematological malignancies
- Integration of liquid biopsy into the clinical workflow for hematological malignancies
- Optimization and normalization of liquid biopsy protocols
- Comparison of different liquid biopsy biomarkers for use in hematological malignancies
- Correlation of liquid biopsy with non-liquid biopsy traditional minimal residual disease techniques
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
